Catalog No.
DHD38518
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20273
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Epratuzumab
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts., PMID:38610966
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus., PMID:38050332
Advances in natural products and antibody drugs for SLE: new therapeutic ideas., PMID:37492083
B cell depletion and inhibition in systemic lupus erythematosus., PMID:36342225
Clinical trials in systemic lupus erythematosus: the dilemma-Why have phase III trials failed to confirm the promising results of phase II trials?, PMID:36202589
Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281
Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia., PMID:35293685
Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis., PMID:34350787
Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models., PMID:34321096
Targeting CD22 for the Treatment of B-Cell Malignancies., PMID:34262884
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies., PMID:33807678
Emerging B-Cell Therapies in Systemic Lupus Erythematosus., PMID:33488082
B cell modulation strategies in the improvement of transplantation outcomes., PMID:32682148
Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies., PMID:32436925
The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis., PMID:31777515
The effect of therapies on the quality of life of patients with systemic lupus erythematosus: a meta-analysis of randomized trials., PMID:31358064
Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials., PMID:31316634
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials., PMID:30575311
Electrochemically Promoted Tyrosine-Click-Chemistry for Protein Labeling., PMID:30422648
Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy., PMID:30372069
Epratuzumab for the treatment of systemic lupus erythematosus., PMID:29542345
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus., PMID:29426575
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials., PMID:29381843
Editorial: Epratuzumab: Reveille or Requiem? Teachable Moments for Lupus and Sjögren's Syndrome Clinical Trials., PMID:29381841
Molecular basis of human CD22 function and therapeutic targeting., PMID:28970495
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia., PMID:28821272
Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis., PMID:28673789
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis., PMID:28673504
Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia., PMID:28666090
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling., PMID:28506291
Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art., PMID:28443384
Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus., PMID:28375452
New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research., PMID:28371318
Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia., PMID:28154086
Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives., PMID:28088906
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial., PMID:27964867
Radioimmunotherapy of lymphoma: an underestimated therapy option., PMID:27964866
Novel Drugs in Follicular Lymphoma., PMID:27872741
Systemic lupus erythematosus: Epratuzumab not effective in phase III trials., PMID:27652506
Biotherapies in systemic lupus erythematosus: New targets., PMID:27663753
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials., PMID:27598855
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia., PMID:27521873
Use of Biologics in Sjögren's Syndrome., PMID:27431344
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22., PMID:27352780
Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus., PMID:27290913
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor., PMID:27125377
Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia., PMID:26921100
Why, why, why de-lupus (does so badly in clinical trials)., PMID:26786849
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study., PMID:26687796
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review., PMID:26654227
For research use only. Not for human or drug use.
